Treatment Algorithm for Metastatic Kidney Cancer

Opinion
Video

The Oncology Brothers and Sumanta Kumar Pal, MD, FASCO, offer comprehensive insights on the treatment of patients with metastatic kidney cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Episode 6: Updates on Genitourinary Cancer Therapies from ASCO 2025
      Episode 6: Updates on Genitourinary Cancer Therapies from ASCO 2025
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
      Incentivizing RCC Research Investment Across Lower-Income Countries
      Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
      Identifying Regional Kidney Cancer Needs Via International Collaboration
      Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
      Using Biopsies to Inform Response Characteristics in Kidney Cancer
      Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
      Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
      Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
      Kidney Cancer Research Consortium Efforts May Improve Treatment Outcomes
      An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
      Kidney Cancer Research Program May Play Pivotal Role in Advancing Care
      Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
      Connecting With Congress to Advance Kidney Cancer Research
      Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
      Collaboration and Research Funding Advancements in Kidney Cancer Advocacy
      Related Content
      A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

      Outpatient Robotic Partial Nephrectomy Is Safe/Feasible for Renal Tumors

      Roman Fabbricatore
      April 29th 2025
      Article

      A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

      Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

      Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

      Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
      May 1st 2025
      Podcast

      Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

      Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

      Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

      Tim Cortese
      March 19th 2025
      Article

      Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      April 1st 2025
      Podcast

      A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

      Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

      Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

      Russ Conroy
      February 26th 2025
      Article

      Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

      LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

      Belzutifan Receives European Approval in Localized/Advanced RCC Indications

      Roman Fabbricatore
      February 18th 2025
      Article

      LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.